Verrica Pharmaceuticals Grants Medomie Pharma Rights To Seek Israeli Regulatory Approval For And To Distribute YCANTH For The Treatment Of Molluscum Contagiosum With Up To $8.2M In Milestones
Under the terms of the Agreement, Verrica has granted Medomie an exclusive right to obtain and maintain marketing authorizations for YCANTH in Israel. Verrica will manufacture YCANTH and provide commercial supply to
Verrica gave another company permission to sell its medicine YCANTH in Israel and could earn up to $8.2 million if certain goals are hit. This shows the company is finding new ways to get its product to more patients around the world.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.